SCHEMBL4677685

SCHEMBL4677685

CC(=O)c1ccc(Cc2nc(CC(=O)C(=O)c3nc[nH]n3)cs2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.37
TSHR P16473 1/20 0.35
HDAC1 Q13547 3/20 0.35
HDAC6 Q9UBN7 3/20 0.35
LMNA P02545 5/20 0.34
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
GAA P10253 1/20 0.33
ALOX12 P18054 1/20 0.33
POLB P06746 1/20 0.33
SMN1; SMN2 Q16637 5/20 0.32
MAPT P10636 4/20 0.32
ALDH1A1 P00352 2/20 0.32
MEN1 O00255 1/20 0.32
NPC1 O15118 1/20 0.32
KDM4E B2RXH2 1/20 0.31
RECQL P46063 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675409 0.92 KMT2A (0.37) KMT2ATSHRHDAC1HDAC6LMNA
SCHEMBL4671892 0.89 BCHE (0.37) KMT2AHDAC1HDAC6LMNACYP1A2
SCHEMBL4674596 0.88 LMNA (0.47) KMT2AHDAC1HDAC6LMNACYP1A2
SCHEMBL4674614 0.87 HDAC1 (0.39) KMT2AHDAC1HDAC6LMNACYP1A2
SCHEMBL4674383 0.87 LMNA (0.40) KMT2AHDAC1HDAC6LMNAGAA
SCHEMBL4676248 0.87 HDAC1 (0.47) KMT2AHDAC1HDAC6LMNAGAA
SCHEMBL4671667 0.86 HDAC1 (0.37) HDAC1HDAC6LMNACYP1A2CYP3A4
SCHEMBL4679026 0.83 XDH (0.38) KMT2ATSHRHDAC1HDAC6LMNA
SCHEMBL4671165 0.81 BCHE (0.39) KMT2APOLBALDH1A1MEN1L3MBTL1
SCHEMBL4671419 0.80 KMT2A (0.40) KMT2ATSHRLMNAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 KMT2A 597/4885TSHR 1614/4885HDAC1 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.